Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.

NEW YORK, April 4, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securities and Exchange Commission, the first amendment to its registration statement on Form S-4, filed on March 15, 2022 (as amended, the "registration statement"), relating to its previously announced proposed business combination with Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, CA.